Photo by nci from unsplash
TPS7581Background: Inhibition of Bruton’s tyrosine kinase (BTK) has emerged as a strategy for targeting B-cell malignancies including CLL/SLL. Zanubrutinib has been shown to be a novel 2nd-generati... Click to show full abstract
TPS7581Background: Inhibition of Bruton’s tyrosine kinase (BTK) has emerged as a strategy for targeting B-cell malignancies including CLL/SLL. Zanubrutinib has been shown to be a novel 2nd-generati...
Keywords:
cll;
zanubrutinib bgb;
3111 bendamustine;
phase zanubrutinib;
bgb 3111;
cll sll
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!